Payment overview · 2025
General Payments
$81.77
4 reported records · 3 companies
Healthcare provider profile · identity verified
Lance Ronald Wehrle, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BLACKFOOT, ID · NPI 1184919607
Verified facts
What the public records show
CMS Open Payments records show Lance Ronald Wehrle, D.O. received $81.77 in general payments during 2025 across 4 reported records.
Novartis Pharmaceuticals Corporation accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.89 | 45.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.50 | 30.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 24.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.77 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 594 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 493 | 135 |
| Losartan Potassium | Losartan Potassium | 442 | 115 |
| Omeprazole | Omeprazole | 427 | 135 |
| Lisinopril | Lisinopril | 355 | 98 |
| Sertraline Hcl | Sertraline Hcl | 252 | 66 |
| Metformin Hcl | Metformin Hcl | 243 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 76 |
| Trazodone Hcl | Trazodone Hcl | 206 | 56 |
| Carvedilol | Carvedilol | 203 | 53 |
| Gabapentin | Gabapentin | 191 | 58 |
| Ozempic | Semaglutide | 187 | 30 |
| Metformin Hcl Er | Metformin Hcl | 184 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 39 |
| Bupropion Xl | Bupropion Hcl | 147 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 40 |
| Famotidine | Famotidine | 141 | 41 |
| Alendronate Sodium | Alendronate Sodium | 129 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 35 |
| Potassium Chloride | Potassium Chloride | 111 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 36 |
| Mounjaro | Tirzepatide | 103 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 39 |
| Glimepiride | Glimepiride | 98 | 26 |
| Furosemide | Furosemide | 94 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 40 |
| Eliquis | Apixaban | 87 | 26 |
| Meloxicam | Meloxicam | 84 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 19 |
| Allopurinol | Allopurinol | 76 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 31 |
| Celecoxib | Celecoxib | 67 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 66 | 17 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Ezetimibe | Ezetimibe | 61 | 15 |
| Farxiga | Dapagliflozin Propanediol | 60 | 19 |
| Finasteride | Finasteride | 57 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 15 |
| Spironolactone | Spironolactone | 56 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Pregabalin | Pregabalin | 54 | 13 |
| Simvastatin | Simvastatin | 52 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 50 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Atenolol | Atenolol | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Prednisone | Prednisone | 26 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 16 |
| Ondansetron Odt | Ondansetron | 24 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.77 · 4 records | Novartis Pharmaceuticals Corporation | GVOKE HYPOPEN, LEQVIO, TZIELD | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error